Earnings Call Is a Requiem for Schering-Plough By Jonathan D. Rockoff Oct. 22, 2009 8:48 am ET Share ...

Novacea has been toiling largely below the radar to develop a Vitamin D-based drug as a new approach to treating advanced prostate cancer. Today, the little company got a big dose ...

Drugmakers Merck & Co. and Schering-Plough Corp., already partners in a joint venture, are planning to merge under the name Merck in a stock-and-cash deal worth about $41.1 billion.

Big Pharma got bigger yesterday with Merck's announcement that it will acquire rival Schering-Plough in a cash-and-stock transaction worth $41.1 billion. And it's being made easier courtesy of U.S ...

Schering-Plough Corp <SGP.N>, reeling from calls for dramatically reduced use of its top-selling cholesterol medicines, on Wednesday announced a cost-cutting program aimed at saving $1.5 billion a ...

Schering-Plough Corp &lt;SGP.N&gt; extended its distribution agreement with Centocor Inc for the rights to market two products, remicade and golimumab, for 15 years after the first golimumab sale.